The FDA has released a new set of educational materials concerning the nature and the prescribing of biosimilar therapies.
The FDA has released a new set of educational materials concerning the nature and the prescribing of biosimilar therapies.
The resources are intended to help educate healthcare providers about biosimilars, and include fact sheets and graphics for clinicians as well as materials that organizations can use as they disseminate information about biosimilars to their stakeholders. The resources provide definitions of key biosimilars terms, describe the standards that a biosimilar therapy must meet before it is granted FDA approval, explains the approval pathway for biosimilar products, explains the FDA’s Purple Book (which lists licensed biologics that have reference product exclusivity as well as those that have biosimilarity or interchangeability evaluations), provides accessible information about the data that the FDA reviews when it determines biosimilarity, and gives additional resources for further reading.
Among the features of the new biosimilars educational site are FDA-sponsored webinars and staff presentations, animated GIFs and other sharable social-media assets, and an up-to-date list of the 7 currently approved biosimilar products.
In a blog post announcing the release of these new materials, FDA Commissioner Scott Gottlieb, MD, and Leah Christl, PhD, associate director for therapeutic biologics in the office of new drugs, a part of the FDA’s Center for Drug Evaluation and Research, said that “Biosimilars can potentially reduce costs for consumers by creating price competition for products that previously faced few market competitors. FDA wants to ensure that health care providers have the information they need when considering prescribing biosimilars when these products are available.”
Gottlieb and Christl also said that the agency plans to continue to engage with healthcare professionals in order to gain feedback on the types of education that they require in order to properly communicate with their patients about biosimilars. These efforts will, the agency hopes, increase the uptake of biosimilar medications, drive down the cost of therapy, and improve access to care.
Recent research has highlighted the need to educate providers about the use of biosimilars; a recent study from Cardinal Health Solutions found that, in a survey of oncologists from practices across the United States, 25% of respondents said that they lacked familiarity with biosimilars, 45% said that their practice partners lacked familiarity, and 46% said that they would require additional evidence concerning biosimilars before they felt comfortable with prescribing a biosimilar therapy for a patient.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.